EE05543B1 - Tuumorinekroositeguri antagonisti kasutamine endometrioosi raviks ette n„htud farmatseutilise kompositsiooni valmistamiseks - Google Patents

Tuumorinekroositeguri antagonisti kasutamine endometrioosi raviks ette n„htud farmatseutilise kompositsiooni valmistamiseks

Info

Publication number
EE05543B1
EE05543B1 EEP200100378A EEP200100378A EE05543B1 EE 05543 B1 EE05543 B1 EE 05543B1 EE P200100378 A EEP200100378 A EE P200100378A EE P200100378 A EEP200100378 A EE P200100378A EE 05543 B1 EE05543 B1 EE 05543B1
Authority
EE
Estonia
Prior art keywords
endometriosis
preparation
treatment
pharmaceutical composition
necrosis factor
Prior art date
Application number
EEP200100378A
Other languages
English (en)
Estonian (et)
Inventor
Borrelli Francesco
D'antonio Mauro
Martelli Fabrizio
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8237393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05543(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200100378A publication Critical patent/EE200100378A/xx
Publication of EE05543B1 publication Critical patent/EE05543B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
EEP200100378A 1999-01-22 2000-01-19 Tuumorinekroositeguri antagonisti kasutamine endometrioosi raviks ette n„htud farmatseutilise kompositsiooni valmistamiseks EE05543B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99101194A EP1022027A1 (en) 1999-01-22 1999-01-22 Tumor necrosis factor antagonists and their use in endometriosis
PCT/IB2000/000052 WO2000043031A1 (en) 1999-01-22 2000-01-19 Tumor necrosis factor antagonists and their use in endometriosis

Publications (2)

Publication Number Publication Date
EE200100378A EE200100378A (et) 2002-10-15
EE05543B1 true EE05543B1 (et) 2012-06-15

Family

ID=8237393

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100378A EE05543B1 (et) 1999-01-22 2000-01-19 Tuumorinekroositeguri antagonisti kasutamine endometrioosi raviks ette n„htud farmatseutilise kompositsiooni valmistamiseks

Country Status (30)

Country Link
US (2) US6663865B1 (ja)
EP (2) EP1022027A1 (ja)
JP (1) JP4601176B2 (ja)
KR (2) KR100685106B1 (ja)
CN (2) CN1212152C (ja)
AR (1) AR022251A1 (ja)
AT (1) ATE242002T1 (ja)
AU (1) AU771964B2 (ja)
BG (1) BG65556B1 (ja)
BR (1) BR0008182A (ja)
CA (1) CA2356737C (ja)
CZ (1) CZ302866B6 (ja)
DE (1) DE60003152T2 (ja)
DK (1) DK1143997T3 (ja)
EA (1) EA003927B1 (ja)
EE (1) EE05543B1 (ja)
ES (1) ES2200808T3 (ja)
HK (2) HK1043059B (ja)
HU (1) HU226149B1 (ja)
IL (2) IL144413A0 (ja)
NO (1) NO328814B1 (ja)
NZ (1) NZ512585A (ja)
PL (1) PL204713B1 (ja)
PT (1) PT1143997E (ja)
SI (1) SI1143997T1 (ja)
SK (1) SK287313B6 (ja)
TR (1) TR200102107T2 (ja)
UA (1) UA78483C2 (ja)
WO (1) WO2000043031A1 (ja)
ZA (1) ZA200105263B (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80676C2 (en) * 2001-01-29 2007-10-25 Applied Research Systems Use of il-18 inhibitors for the treatment and/or prevention of cardiomyopathy
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1709965A3 (en) 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediate diseases
US7082134B1 (en) * 2002-01-18 2006-07-25 Juniper Networks, Inc. Redirect checking in a network device
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20070298041A1 (en) * 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
ATE416783T1 (de) * 2003-02-07 2008-12-15 Austria Wirtschaftsserv Gmbh Verwendung des menschlichen choriongonadotropins in der behandlung von endometriose-symptomen
AU2004270733B2 (en) 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors
GB0327112D0 (en) 2003-11-21 2003-12-24 Clincial Designs Ltd Dispenser and reservoir
GB0408449D0 (en) 2004-04-15 2004-05-19 Banerjee Subhasis Diagnostic and therapeutic applications of soluble lhcge protein
CA2565801A1 (en) * 2004-05-28 2005-12-15 Applied Research Systems Ars Holding N.V. Use of il-17 in the treatment of fertility-related disorders
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
JP5544458B2 (ja) * 2005-07-12 2014-07-09 アンピオ ファーマシューティカルズ，インコーポレイテッド 疾病を治療するための医薬製品の製造においてトリロスタンｉｉｉを使用する方法及びトリロスタンｉｉｉを含む医薬製品
BRPI0812398A2 (pt) * 2007-06-06 2019-09-24 Domantis Ltd domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
SG2014009799A (en) 2009-06-22 2014-04-28 Ampio Pharmaceuticals Inc Method for treatment of diseases
AU2010264525B2 (en) * 2009-06-22 2015-04-02 Ampio Pharmaceuticals, Inc. Methods and products for treatment of diseases
WO2014100352A1 (en) 2012-12-19 2014-06-26 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
AU2016226414B2 (en) 2015-03-02 2021-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an IL-33 antagonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037805A (en) * 1989-03-20 1991-08-06 The Salk Institute For Biological Studies Methods of contraception
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
DE07012625T1 (de) * 1991-03-18 2010-01-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
EP0620739A4 (en) * 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
US5389657A (en) * 1993-02-01 1995-02-14 Free Radical Sciences Corporation Method for treating infertility
IL111125A0 (en) * 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US5747532A (en) * 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5710247A (en) * 1996-03-19 1998-01-20 Abbott Laboratories Process and intermediates for the synthesis of LHRH antagonists
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
ES2326347T3 (es) * 1996-11-27 2009-10-07 Immunex Corporation Metodo para regular la produccion de oxido nitrico.
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors

Also Published As

Publication number Publication date
CN1337883A (zh) 2002-02-27
NO20013577D0 (no) 2001-07-19
PT1143997E (pt) 2003-10-31
PL204713B1 (pl) 2010-02-26
UA78483C2 (en) 2007-04-10
JP4601176B2 (ja) 2010-12-22
EP1143997B1 (en) 2003-06-04
JP2002535284A (ja) 2002-10-22
CN1698894A (zh) 2005-11-23
SK287313B6 (sk) 2010-06-07
EE200100378A (et) 2002-10-15
HU226149B1 (en) 2008-05-28
AU771964B2 (en) 2004-04-08
KR100685106B1 (ko) 2007-02-22
SI1143997T1 (en) 2003-12-31
EP1143997A1 (en) 2001-10-17
IL144413A0 (en) 2002-05-23
EA003927B1 (ru) 2003-10-30
CZ302866B6 (cs) 2011-12-21
DE60003152D1 (de) 2003-07-10
NO328814B1 (no) 2010-05-18
HUP0105103A2 (hu) 2002-04-29
HK1082690A1 (en) 2006-06-16
BR0008182A (pt) 2001-11-06
DE60003152T2 (de) 2004-03-25
BG105691A (en) 2002-02-28
AU1997300A (en) 2000-08-07
US20040057954A1 (en) 2004-03-25
US6663865B1 (en) 2003-12-16
EP1022027A1 (en) 2000-07-26
HK1043059A1 (en) 2002-09-06
ZA200105263B (en) 2002-06-26
HUP0105103A3 (en) 2004-08-30
IL144413A (en) 2009-05-04
BG65556B1 (bg) 2008-12-30
ATE242002T1 (de) 2003-06-15
CA2356737A1 (en) 2000-07-27
KR20010101397A (ko) 2001-11-14
HK1043059B (zh) 2005-11-18
ES2200808T3 (es) 2004-03-16
SK10292001A3 (sk) 2001-12-03
AR022251A1 (es) 2002-09-04
EA200100799A1 (ru) 2001-12-24
WO2000043031A1 (en) 2000-07-27
NZ512585A (en) 2003-08-29
PL350002A1 (en) 2002-10-21
KR20060128056A (ko) 2006-12-13
CN100594932C (zh) 2010-03-24
TR200102107T2 (tr) 2001-12-21
CA2356737C (en) 2010-03-23
DK1143997T3 (da) 2003-09-15
CZ20012656A3 (cs) 2002-02-13
CN1212152C (zh) 2005-07-27
NO20013577L (no) 2001-08-29

Similar Documents

Publication Publication Date Title
EE05543B1 (et) Tuumorinekroositeguri antagonisti kasutamine endometrioosi raviks ette n„htud farmatseutilise kompositsiooni valmistamiseks
NO20022970D0 (no) Hydrogel-drevet medikamentdoseringsform
NO20020464D0 (no) Flerkomponent-farmasöytisk doseringsform
DK1158992T3 (da) Anvendelse af xenon til fremstilling af et farmaceutisk præparat til behandling af neurointoksikationer
HUP0004120A3 (en) Use of cgmp-pde5 inhibitors for the preparation of pharmaceutical compositions treating neuropathy
EE05481B1 (et) Kinasoliini derivaadid kasvajate raviks
HUP0600593A3 (en) Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents and pharmaceutical compositions thereof
IL158306A0 (en) Pharmaceutical dosage form of amorphous nelfinavir mesylate
EE200100717A (et) Indasooliühendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ja meetodid nende kasutamiseks
NO20021400L (no) Terapeutiske kinazolinderivater
EE200200656A (et) Ravis kasutatavad tropaani derivaadid
EE05378B1 (et) LahustuvaÁCTLA4ÁsulandmolekuliÁkasutamineÁravimkoostiseÁvalmistamiseks
NO20030627D0 (no) Hydrogel-drevet medikament doseringsform
HUP0202319A3 (en) Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
GB0117618D0 (en) Pharmaceutical dosage form
IL164896A (en) Pharmaceutical compositions comprising immunoconjugates for the treatment of tumors
GB0117619D0 (en) Pharmaceutical dosage form
NO20015149D0 (no) Nytt farmasöytisk preparat
FI20000780A (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
NO20015148L (no) Nytt farmasöytisk preparat
HUP0102159A3 (en) Pharmaceutical composition for the treatment of rumen acidosis
NO20015104L (no) Nytt farmasöytisk preparat
IL137275A0 (en) Pharmaceutical composition for the treatment of anal fissures
HUP0302629A3 (en) Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer
NO20015105L (no) Nytt farmasöytisk preparat

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20130119